GlassScriptPhysician profile
Rafael Okamoto
NPI 1235281874
$4,988.73
in general payments reported to CMS, 2019-2025
28 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $912 · 2021: $932 · 2022: $393 · 2023: $245 · 2024: $179 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $984.70 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $817.54 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $693.95 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $384.72 | 2019-2022 | |
| Pfizer INC. | $351.41 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $243.67 | 2019-2022 | |
| Galderma Laboratories, L.P. | $218.64 | 2021-2022 | |
| Abbvie INC. | $207.63 | 2021-2025 | |
| Lilly USA, LLC | $191.47 | 2020-2024 | Jardiance, Emgality |
| Amgen INC. | $178.43 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $139.41 | 2019 | |
| Daiichi Sankyo INC. | $109.08 | 2021-2025 | Injectafer |
| Glaxosmithkline, LLC. | $85.49 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $46.23 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.49 | 2020 | |
| Amarin Pharma, INC. | $35.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.25 | 2020-2021 | |
| Life Spine, INC. | $30.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.12 | 2019 | |
| Eisai INC. | $17.82 | 2020 | |
| Ethicon US, LLC | $16.91 | 2019 | |
| Melinta Therapeutics, LLC | $16.09 | 2019 | |
| Genentech USA, INC. | $15.73 | 2019 | |
| Mannkind Corporation | $15.55 | 2019 | |
| Exact Sciences Corporation | $15.49 | 2025 | The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $14.24 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Okamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.